is currently solvent and making every effort to stay that way.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS: http://biz.yahoo.com/iw/051118/0101735.html
Press Release Source: DNAPrint genomics, Inc.
DNAPrint genomics to Present at Investor Conference Sponsored by the Wall Street Analyst Forum
Friday November 18, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Nov 18, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that Dr. Barbara Handelin, the Company's General Manager of Computational Biology, will be presenting before The Wall Street Analyst Forum Institutional Investor Conference at The Roosevelt Hotel, Madison Avenue at 45th Street, in New York City at 11:00 a.m. Eastern time on Wednesday, November 30.
During the 40-minute presentation, which can also be heard via a live webcast on the Company's website at www.dnaprint.com or at http://www.investorcalendar.com/CEPage.asp?ID=97888, Dr. Handelin will provide an overview of the Company and discuss its goals and outlook for the future. The webcast will also be archived. To register for the conference, please visit www.analyst-conference.com or contact The Wall Street Group, Inc. at 212-888-4848.
The Wall Street Analyst Forum brings together financial analysts and portfolio managers who are interested in learning about the companies participating in the investor conference and provides them the opportunity to personally meet company personnel and learn more about the company.
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
ADVERTISEMENT
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint genomics, Inc.
NEWS:
http://biz.yahoo.com/iw/051117/0101554.html
DNAPrint genomics CEO Richard Gabriel Featured in Interview in Wall Street Transcript's Biotechnology Issue
Thursday November 17, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Nov 17, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News) today announced that The Wall Street Transcript has published a biotechnology issue which features a comprehensive interview with Richard Gabriel, the Company's President and Chief Executive Officer.
During the interview Mr. Gabriel traces how DNAPrint genomics has evolved into a company focused on three areas: pharmacogenomics and the development of personalized test/drug combinations called theranostics; genealogy, which is basically a consumer ancestry product, and forensics for law enforcement. "Pharmacogenomics is the Company's biggest market opportunity, and we've focused on developing pharmaceutical applications for our products and services," he stated.
The interview is available the Company's website at www.dnaprint.com and can be accessed by subscribers on the Transcript's Web site (www.twst.com).
The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
President and CEO
941-366-3400
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint Genomics, Inc.
Nobody in chat anymore?
Hey! What gives man??!! I turned my resignation in just before punching out tonite {nice guy that I am I decided to finish the day out} and I come home to find out I'm still a pauper. Now I'm not sure how to 'splain to my wife about the new 'Stang in the driveway................ or the dancing girls for that matter...
Jeeves how could you do me so wrong?? {puppy dog eyes} I'm beginning to think that maybe, just maybe, {Sherlock Holmes look} you really don't know what you're talking about.
Theo
Well Jeves my man, looks like your prediction for news tomorrow is not holding much sway in the investment world here in DNAG land. I posted a few days ago several links to posts from different boards that were obviously watching DNAG's movement/volume. Today's lack of movement the day before supposedly "... Big Big Big News! leads me to believe that my version probably has more merit. I suspect a concerted effort was/is in place to load up/front-run and then momo DNAG. Problem is, more shares were unloaded into the volume Friday effectively curtailing the momentum for the run hence a subsequent stall and now a retraction... I'm beginning to wonder about you Jeves. I certainly hope you don't wind up like TexMex, or the "Rocketeers" from years ago. These were organized groups {one of many} who proliferated the message boards {before iHub} known for front-running and momo plays. Silicon Investors was the "biggie" at that time. I made a huge windfall from one of their "runs" and all by accident. I just happened to have bought into a stock that turned out to be one their "plays" {INFE at the time}. I just thought it was a good long term prospect because of a low float among other things, but, Joe and his group had decided to make that stock a "play". All got caught up in momo tactics and then legal hassles. Anyway, hope you're not getting involved in some sort of shady shenanigans too Jeves...
DNAG appears to be still building/growing and as I've said in the past, as long as they do I will support them. Not blindly, but will still support them.
Theo
Still more players, traders, investors watching DNAG's action:
http://www.investorshub.com/boards/read_msg.asp?message_id=8375971&txt2find=dnag+
Theo
Jever00, Jever00, Jever00... what are we gonna do with you? LOL!!!
"MY PREDICTION IS GOING TO BE RIGHT ON...."
FYI- MOMO players abound and are watching/playing folks. Nothing wrong with it but just be aware...
http://www.investorshub.com/boards/replies.asp?msg=8359086
http://www.investorshub.com/boards/read_msg.asp?message_id=8359086&txt2find=dnag+
MOMO Board-
http://www.investorshub.com/boards/read_msg.asp?message_id=8359086&txt2find=dnag+
DayTrader's board-
http://www.investorshub.com/boards/read_msg.asp?message_id=8362694&txt2find=dnag+
Hunchtrades Board
http://www.investorshub.com/boards/read_msg.asp?message_id=8364000&txt2find=dnag+
Early Bird Special Board-
http://www.investorshub.com/boards/replies.asp?msg=8364186
Theo
News: DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data
http://biz.yahoo.com/pz/051027/88606.html
Thursday October 27, 7:00 am ET
SARASOTA, Fla., Oct. 27, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.
ADVERTISEMENT
``Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality,'' stated Tony N. Frudakis, Ph.D., DNAPrint's founder and Chief Scientific Officer. ``The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community.''
Geneticists use ``molecular addresses'' to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar ``sequence'' addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.
This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint's unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a ``Super EPO'' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA.
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
DNAPrint genomics, Inc.
Richard Gabriel, President and CEO
(941) 366-3400
The Wall Street Group, Inc.
Ron Stabiner
(212) 888-4848
Source: DNAPrint genomics, Inc.
News:http://biz.yahoo.com/prnews/051024/dem032.html?.v=20
Press Release Source: Arcadia Resources, Inc.
Arcadia Resources Acquires Select Assets of Sparrow Development to Expand Services in Mid-Michigan
Monday October 24, 3:09 pm ET
SOUTHFIELD, Mich., Oct. 24 /PRNewswire-FirstCall/ -- Arcadia Resources, Inc. (OTC Bulletin Board: ACDI - News), a leading national provider of home care and staffing services, including travel nursing, mail-order pharmacy and durable medical equipment (DME), announced today that Arcadia Health Services of Michigan, Inc. has acquired select private duty home care services assets from Sparrow Development, Inc., a holding company of the Sparrow Health System in Lansing, Michigan. Sparrow Development is an affiliate of Sparrow Health System, a major provider of inpatient, outpatient, and home care services serving the mid-Michigan markets.
ADVERTISEMENT
Larry Kuhnert, president of Arcadia Resources, stated, "By acquiring Sparrow private duty services' assets, we not only add value to our existing service offerings, but also can realize significant sales and cost synergies through the integration of these assets under our centralized location in Lansing, MI. We expect this acquisition will be accretive to our earnings beginning in 2005."
Susan M. Powell, Administrative Director of Sparrow Private Duty Services, stated, "We are excited to be working with the Arcadia team of professionals. For the patients and employees of Sparrow private duty services, we believe Arcadia offers expanded access to a leading, nationwide home health care agency to continue to deliver expert services to our community."
About Arcadia Resources, Inc.
Arcadia Resources, Inc. operations include home health care services; non-medical and medical staffing, including travel nursing; provision of respiratory and durable medical equipment to patients in the home; a full service mail-order pharmacy; and a mail-order catalog of home health care- oriented products. The Company's comprehensive solutions help organizations operate more effectively and with greater flexibility, while enabling individuals to manage illness and injury in the comfort of their own homes.
Arcadia Resources is the product of the May 2004 merger of Critical Home Care, Inc. and RKDA, the parent company of Arcadia Services, Inc., and Arcadia RX, LLC. Since June 30, 2004, the Company has acquired several successful staffing and home health care businesses in Alabama, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, North Carolina and South Carolina, along with a mail-order catalog business. For more information, visit: http://www.arcadiaresourcesinc.com .
Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission.
For more information:
National Financial Network
Geoffrey Eiten, Investor Relations
781-444-6100 x613
geiten@nationalfc.com
http://www.nfnonline.com/acdi
Source: Arcadia Resources, Inc.
wantahummer2,
I'm going to assume that your vituperation was directed to Jeevers and not to me...
Jeeves, others may despise you, however, I like you because you make me smile...
One of these days you will hit it dead on and be "the star".
Theo;)
NEWS: http://biz.yahoo.com/iw/051020/098525.html
Not sure why I post this- nobody seems to notice until someone else actually points it out... lol!
News:
http://biz.yahoo.com/prnews/051012/dew024.html?.v=25
Arcadia Resources Enters South Carolina Market with Acquisition of Medical Equipment Company
Wednesday October 12, 2:10 pm ET
SOUTHFIELD, Mich., Oct. 12 /PRNewswire-FirstCall/ -- Arcadia Resources, Inc. (OTC Bulletin Board: ACDI - News), a leading national provider of home care and staffing services, mail-order pharmacy and durable medical equipment (DME), announced today that it has acquired the business of Medical Equipment Company, a respiratory and durable medical equipment supplier based in Walterboro, South Carolina. Walterboro, located in southern South Carolina near the junction of US Highway 17A and Interstate Highway 95, is the largest city in Colleton County and the county seat. This acquisition marks the Company's first entrance into the state of South Carolina.
ADVERTISEMENT
"We are excited about working with Arcadia and their staff. As a public company with an outstanding reputation in the home care industry, Arcadia brings resources to our community that were not previously available. We see great future potential in serving new and existing customers by joining Arcadia," said Mark Baty, President of Medical Equipment Company.
"We look forward to supporting the experienced staff of Medical Equipment Company, and assisting them with growth opportunities in the surrounding areas," stated Judy Berchelmann, National Director of Marketing for Arcadia Resources.
Larry Kuhnert, president of Arcadia Resources, stated, "We continue to be focused on expanding Arcadia's position as a leading provider of home health care products and services. This acquisition provides us with an initial presence in the South Carolina marketplace from which we can grow. Expanding our market share through the purchase of firms that meet our quality and financial standards is an important component in the growth plans of our company."
About Arcadia Resources, Inc.
Arcadia Resources, Inc. operations include home health care services, medical and non-medical staffing, provision of respiratory and durable medical equipment to patients in the home, a full service mail-order pharmacy and a mail-order catalog of home health care-oriented products. The Company's comprehensive solutions help organizations operate more effectively and with greater flexibility, while enabling individuals to manage illness and injury in the comfort of their own homes.
Arcadia Resources is the product of the May 2004 merger of Critical Home Care, Inc. and RKDA, the parent company of Arcadia Services, Inc., and Arcadia RX, LLC. Since June 30, 2004, the Company has acquired several successful staffing and home health care businesses in Alabama, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, North Carolina and South Carolina, along with a mail-order catalog business. For more information, visit: http://www.arcadiaresourcesinc.com .
Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission.
For more information:
Investor Relations Contact
National Financial Network
Geoffrey Eiten
781-444-6100 x613
geiten@nationalfc.com
http://www.nfnonline.com/acdi
Source: Arcadia Resources, Inc.
I never see it- I'm thinking I'm gonna havta copy the animation to my own web page an link it from there instead of linking from the original site...
Theo
News:
1)http://biz.yahoo.com/prnews/051003/dem031.html?.v=17
2)http://biz.yahoo.com/prnews/051003/dem034.html?.v=13
*********************************************************
Arcadia Resources Closes $31 Million Private Placement to Accelerate M&A Strategy
Monday October 3, 2:40 pm ET
SOUTHFIELD, Mich., Oct. 3 /PRNewswire-FirstCall/ -- Arcadia Resources, Inc. (OTC Bulletin Board: ACDI - News), a leading provider of home care and staffing services, mail-order pharmacy and durable medical equipment ("DME"), announced today that it has completed its private placement financing totaling $31 million. The net proceeds have been used to recapitalize the balance sheet of the Company, with the remainder earmarked to fund merger and acquisition activities. Details of the transaction can be found in the Company's Form 8-K filed at http://www.sec.gov on September 30, 2005. John E. Elliott II, chairman and CEO of Arcadia Resources, Inc., stated, "With this substantial funding, we have strengthened our balance sheet, including eliminating approximately $23 million or 75% of our interest-bearing debt. We are now in a more favorable position to step up the Company's acquisition momentum within the home health care services industry. In addition to strategic M&A activities, this funding supports the execution of enhanced marketing programs and should help facilitate expansion among our local service providers, including growing our kiosk presence within select Sears stores. We expect to continue to advance our position as one of the nation's leading integrated home health care services providers."
**********************************************************
Arcadia Resources Opens Home Health Care Centers at Six Detroit-Area Sears Stores
Monday October 3, 3:21 pm ET
SOUTHFIELD, Mich., Oct. 3 /PRNewswire-FirstCall/ -- Arcadia Resources, Inc. (OTC Bulletin Board: ACDI - News), as a licensed business partner of Sears, Roebuck and Co., announced today that it has launched "Sears Home Health Care," a dedicated store area for products that promote home care, personal independence and medical well-being. The Home Health Care centers are now operating in six Sears stores in the metropolitan Detroit area. Arcadia Resources created the concept and is responsible for the development and operation of Sears Home Health Care centers. Arcadia Resources is a leading national provider of home care and staffing services, mail-order pharmacy and durable medical equipment (DME).
Detroit was selected for the launch because it is one of Sears' strongest markets in the United States. In addition, the Detroit market has a significant population of active consumers in their late 40s through their 70s and 80s, a primary target for the new Sears Home Health Care centers.
"The Sears Home Health Care centers are designed to serve the growing population of adults who are seeking homecare solutions that allow them to maintain an active and independent lifestyle," said John Elliott II, chairman and CEO of Arcadia Resources, Inc. "While many of the products benefit consumers of all ages, there is a specific need among mature adults for homecare products and medical equipment that help them achieve and preserve the lifestyle they desire."
Sears Home Health Care centers feature a distinct identity to distinguish them from surrounding products and departments. Each center includes more than 1,000 products ranging from mobility devices such as wheelchairs, scooters, stairway lifts and walkers, to orthopedic support, bathroom safety and adjustable beds.
"Sears Home Health Care centers make it possible for people to shop for home health care products in a comfortable setting staffed by experienced health professionals," said Larry Kuhnert, President of Arcadia Resources, Inc.
Impressive 1 year chart
Paulwarn,
I've done similar {smaller scale} back-testing of these tout sheets as well and have always wanted to do a large scale test but never had the time. In the back of my mind I was plotting a strategy to see if I could use this type of manipulation for short-term scalping, but, alas my results were identical to those of Joshua Cyr of Spamstocktracker.com "...almost ALL of those stocks I added went up a few cents max, then dropped like flies the next day. So much for short-term gains." Thanks for sharing as my curiosity won't be tempted further LOL!
Theo
Showing some life?? Up almost 7% so far today...
Theo
Yeah, Geob I think the day-traders are loading up... Well, even though I've got the day off, I still gotta go work out. I may havta consider adding to my position when I get back if the volume is sustained... interesting for sure.
Theo
Keep an eye on the volume - Message #33352
http://www.investorshub.com/boards/read_msg.asp?message_id=7837537
"...still buying- cost average including pre post split is under a nickle now... highly speculative, but the volume last week tells me that there are, if nothing else, "players" out there who intend to ride a buying binge once DNAG does provide the catalyst. The volume and subsequent sell-off last week also suggests that Jever in not the only person who suspects "something" on the horizon. Let's see what the volume does this Thursday and Friday. Regardless of what Jeever states, the real telling sign of impending "good" news will be volume in advance.
Theo
Team- sorry can't buy it. Momos get started before PRs come out as would the volume. And speaking of volume- way too much volume to start the day {and a Monday at that} as well. Now, I might be persuaded to believe that perhaps another "play" might be in the works in the near future. :)
Ah, the suspense never ends...
Theo
Bid 0.021 Ask 0.213 and what's with the volume this a.m.?
Volume 15,852,518
Geob Re: Phenylpropanolamine This warning is 5 years old. While somewhat legitimate then, not very likely you have any of the medication that is of concern now...
http://urbanlegends.about.com/b/a/147163.htm
Thanks for taking the time to post the compete exchange Stefan. Your effort was/is very much appreciated.
Theo
NEWS:
http://www.primezone.com/newsroom/news.html?d=86765
Source: DNAPrint genomics, Inc.
DNAPrint genomics Completes Initial Research for Production of Company's First Pharmaceutical Product
New Super EPO Test/Drug Combination Enters Preclinical Development Stage
SARASOTA, Fla., Sept. 27, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTCBB:DNAG) today announced the completion of initial research for the production of PT-401, a more powerful version of the anemia drug Erythropoietin (EPO), which has advanced into the preclinical development stage for the Company's first pharmaceutical product.
"Our research surveyed several potential host cells for the production of PT-401," stated Hector Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We have selected one that the research indicates will provide superior glycosylation, which is critical for the processing of PT-401. We anticipate that this will lead to greater therapeutic efficacy and later on will be beneficial to expediting regulatory approval. In addition, we have optimized the structure of the gene encoding PT-401, thus providing excellent production efficiency and an optimal structure/activity profile of the active compound. Our production schedule remains on target."
DNAPrint(tm) obtained an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) in February 2005 for the development of a "Super" EPO, a more potent and longer acting form of Erythropoietin (EPO), which has a worldwide market exceeding $10 billion and which is growing at an average annual rate of 21%. Production of a Super EPO dimer is central to DNAPrint's overarching strategy to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called "Theranostics," which maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors. In June 2005, DNAPrint selected Proteos, Inc., to handle pre-clinical analysis of PT-401 and to manufacture the first batch of the new drug.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm).
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics Inc.
Richard Gabriel
President and CEO
(941) 366-3400
The Wall Street Group, Inc.
Ron Stabiner
(212) 888-4848
Bought 'nother round today- MMs would not take the bait for past three days @ .015 so I gave in to them at their price. Maybe perhaps, just maybe we're sitting on the floor. Of course now that I said that come Monday... :(
Theo
NEWS:
DNAPrint genomics to Discuss Role of Eye Color Testing During International Biometrics Web Symposium
http://biz.yahoo.com/pz/050922/86498.html
Never said I was happy with the events- but at this point I'm covering my proverbial investing backside- sliding my PPS break-even point to more manageable level. A saying from a poster who I have followed for many years {Jim Bishop}- "Go to the dance, but dance close to the door" has served me well in the past and I continue to follow that same mantra.
"Surber is a Utah based punk." You're one up on me- never heard of him, but thanks for the heads up. I'm more heavily invested in other stocks therefore you are correct- I'm not paying attention to details such as Richard Surber. While I still like the science, the business segment has left me no alternative but, to work the trading aspect of this stock to recoup investment dollars. If and when DNAG proves more reliable and stable, I will be more inclined to "invest" rather than trade...
Theo
Re: Funding-
..."I spoke to Gabriel today about the financing situation and he wants to get rid of la jolla and dutchess with this next financing, I believe it might be coming out of Europe..."
Might not be to far off the mark. Who, what , and where is the question. Might also explain Jeever's insistence that DNAG is "holding back on us" on some sort of "news. I've kinda suspected that Jeever's propensity for claiming clairvoyance capabilities {when it comes to predicting news} is probably coming from overseas sources as his timing leaves a lot to be desired but has appeared none-the-less. Lack of timing ability tells me that his "information" is most likely NOT coming from sources within the company itself- which leads me to further speculate that Jeever probably has, instead, a "contact" who is a friend of a friend, etc., who may be a fly-on-the-wall in an entity other than DNAG but none-the-less has business dealings with DNAG. Speculation on my part, but, provides comic relief in the interim...
Still buying- cost average including pre post split is under a nickle now... highly speculative, but the volume last week tells me that there are, if nothing else, "players" out there who intend to ride a buying binge once DNAG does provide the catalyst. The volume and subsequent sell-off last week also suggests that Jever in not the only person who suspects "something" on the horizon. Let's see what the volume does this Thursday and Friday. Regardless of what Jeever states, the real telling sign of impending "good" news will be volume in advance.
JMHO
Theo
Are you sure they didn't mention Dnaprint Genomics? I thought I heard the narrator say "...from a little {or little known} company in Florida called Dnaprint Genomics..."
Anyway, I found it entertaining and well done especially the interview with Dr. frudakis- even learned a couple of new facts I hadn't known prior.
FWIW, I have made two purchases of stock the past two weeks- one last week and one today at the open- am buying at these levels. I'm not afraid to go to the dance- but, I do dance close to the door...
Theo
Very entertaining episode on Court TV. Now, if only law enforcement will spend a gazillion dollars on DNAG's testing... ;)
Sorry bag8ger, you and I disagree. Revenues are a direct reflection of the fundamentals therefore I certainly do not over look them. Second, while the R/S was necessary and almost an absolute given when we authorized the 1.5 billion, the pending dilutive potential of the 1.5 bil is still overhang no matter how you cut it. The market knows it and the market is ruthlessly efficient- hence the depressed PPS and will continue to suppress real significant gain. The 1.5 billion overhang is also, I might add, a part of the "fundamentals" package that any investor will look at. Doesn't mean we won't make it, just that it will take significantly longer and more effort- JMHO.
Theo
Front page of USA Today is nice and I'll take the exposure anytime, however, I'll let you in on a little secret- DNAG is not gonna "go to the moon" with the baggage of an R/S and 1.5 billion authorized and ready to dilute anytime soon IMO without revenues. Exposure is great- but cash is still king. Sorry folks, I've been here since the CLYC days and even bought some more this week {which I continue to hold even after the price spike today}. The difference is I did NOT get attached to DNAG to the extent that I rode it into the ground and I happen to think that before the end of the year I should be able to make a decent profit again. While I firmly still believe DNAG has a chance of making it big-time I also think that those who held WITHOUT trading, especially the past couple of years, have nobody but themselves to blame. I've lost money here in some years and made a bundle in others. I have never given up on the company, but I refuse to let emotion govern my trading decisions. If todays action did not have the aforementioned drawbacks associated with it, we would have climbed into the teens and higher without a doubt. In fact, if we just got rid of the potential dilution overhang, we would be half a buck or more just on speculation IMO. But, we DO have that dilution potential skeleton hanging in our investment closet and it does not appear that it will go away anytime soon. That does NOT mean I think we fail. On the contrary, those that have followed me for years here and on RB and on Silicon Investors know that I have ALWAYS stated that "as long as DNAP {DNAG} continues to grow and follow its primary business plan {sic}, I will continue to support them." That doesn't and didn't mean I would follow them into the ground. DNAG has dug themselves a big hole to climb out of- I think they can do it, but, Jevers' news prognostications alone is NOT the way it is going to prosper. We all know or should know that revenues are the ONLY way at this point we can increase shareholder value above the penny ante movements we have had to live with the past few years. In addition how many of just you folks here in IHub land alone are itching to hit the "sell" button as soon as your predetermined "get out" price is reached? We saw it today. As soon as buying drives the price up, it gets hit by the traders. I suspect we will see choppy trading for awhile until enough shares have been sprung loose {or dumped by the the less-than-enthused long waiting to fold} before we can establish any kind of base on the trading floor. In the meantime, I will keep buying and selling and continue to add to my pot "free" shares as it will allow me. Thanks for the soapbox!
Theo
LG,
I have absolutely no idea who Thelonegunmen is and I couldn't possibly care less. I will also admit to having had my alias used "in vain" in the past as well and can sympathise. However, I am somewhat taken aback by your sudden conviction that this particular stock is a scam. "Maybe your insulting behavior will encourage me to look into this one..." Are we to take that as some sort of threat? I apologize if you're sincerely interested in looking into this stock and your intentions are truly altruistic, but one can't help but notice the antagonistic tone in which you offer yourself. With that being said, I really would appreciate your insight. Having an "unbiased" pair of eyes giving their opinion would be valuable IMO. So, if you can get past the sophomoric bravado and weiner measuring contests then please, by all means, have at it and knock yourself out...
Theo
Speculation of "future" revenues, breakthroughs, and the current reduced float will coax upward pressure on the share price while the actual dilution will deflate the effort. Where it winds up is totally dependent on the point in time you choose and the goals reached... In the meantime the "market" tends to be ruthlessly efficient- 0.007 was were we left off prior to the split and as of yet, there is nothing {i.e., revenues} to serve as a catalyst to move the share price up other than speculation. Hope and faith is what we counted on before and appears to be what will be needed yet for a little while longer. The game is still afoot dear Watson...
Theo
Not a problem Arch... I post so rarely at this juncture in time that when I glanced over my own profile tonite {just for laughs and giggles} I realized I hadn't updated my age for a could of years... :-/ Trust me I know the feeling... ;)
Theo
You can call me "somebody" or Theo... doesn't matter... :)
g'nite!
Theo